199 related articles for article (PubMed ID: 23698748)
1. Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo.
Foy KC; Wygle RM; Miller MJ; Overholser JP; Bekaii-Saab T; Kaumaya PT
J Immunol; 2013 Jul; 191(1):217-27. PubMed ID: 23698748
[TBL] [Abstract][Full Text] [Related]
2. Peptide vaccines of the HER-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo.
Allen SD; Garrett JT; Rawale SV; Jones AL; Phillips G; Forni G; Morris JC; Oshima RG; Kaumaya PT
J Immunol; 2007 Jul; 179(1):472-82. PubMed ID: 17579068
[TBL] [Abstract][Full Text] [Related]
3. B-cell epitope peptide vaccination targeting dimer interface of epidermal growth factor receptor (EGFR).
Zhu L; Zhao L; Wu M; Chen Z; Li H
Immunol Lett; 2013 Jun; 153(1-2):33-40. PubMed ID: 23871733
[TBL] [Abstract][Full Text] [Related]
4. Novel engineered trastuzumab conformational epitopes demonstrate in vitro and in vivo antitumor properties against HER-2/neu.
Garrett JT; Rawale S; Allen SD; Phillips G; Forni G; Morris JC; Kaumaya PT
J Immunol; 2007 Jun; 178(11):7120-31. PubMed ID: 17513761
[TBL] [Abstract][Full Text] [Related]
5. A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses.
Dakappagari NK; Pyles J; Parihar R; Carson WE; Young DC; Kaumaya PT
J Immunol; 2003 Apr; 170(8):4242-53. PubMed ID: 12682258
[TBL] [Abstract][Full Text] [Related]
6. Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice.
Wagner S; Jasinska J; Breiteneder H; Kundi M; Pehamberger H; Scheiner O; Zielinski CC; Wiedermann U
Breast Cancer Res Treat; 2007 Nov; 106(1):29-38. PubMed ID: 17203384
[TBL] [Abstract][Full Text] [Related]
7. In Silico Approach in Designing a Novel Multi-Epitope Vaccine Candidate against Non-Small Cell Lung Cancer with Overexpressed G Protein-Coupled Receptor 56.
Herrera LRM
Asian Pac J Cancer Prev; 2020 Aug; 21(8):2297-2306. PubMed ID: 32856858
[TBL] [Abstract][Full Text] [Related]
8. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine.
Dakappagari NK; Douglas DB; Triozzi PL; Stevens VC; Kaumaya PT
Cancer Res; 2000 Jul; 60(14):3782-9. PubMed ID: 10919651
[TBL] [Abstract][Full Text] [Related]
9. Immunization with synthetic VEGF peptides in ovarian cancer.
Wang B; Kaumaya PT; Cohn DE
Gynecol Oncol; 2010 Dec; 119(3):564-70. PubMed ID: 20822802
[TBL] [Abstract][Full Text] [Related]
10. A novel recombinant anti-epidermal growth factor receptor peptide vaccine capable of active immunization and reduction of tumor volume in a mouse model.
Asadi-Ghalehni M; Rasaee MJ; RajabiBazl M; Khosravani M; Motaghinejad M; Javanmardi M; Khalili S; Modjtahedi H; Sadroddiny E
Microbiol Immunol; 2017 Dec; 61(12):531-538. PubMed ID: 29023946
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations.
Perez-Torres M; Guix M; Gonzalez A; Arteaga CL
J Biol Chem; 2006 Dec; 281(52):40183-92. PubMed ID: 17082181
[TBL] [Abstract][Full Text] [Related]
12. A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy.
Kaumaya PT
Hum Vaccin Immunother; 2015; 11(6):1368-86. PubMed ID: 25874884
[TBL] [Abstract][Full Text] [Related]
13. In silico design of discontinuous peptides representative of B and T-cell epitopes from HER2-ECD as potential novel cancer peptide vaccines.
Manijeh M; Mehrnaz K; Violaine M; Hassan M; Abbas J; Mohammad R
Asian Pac J Cancer Prev; 2013; 14(10):5973-81. PubMed ID: 24289611
[TBL] [Abstract][Full Text] [Related]
14. Vaccination with ErbB-2 peptides prevents cancer stem cell expansion and suppresses the development of spontaneous tumors in MMTV-PyMT transgenic mice.
Gil EY; Jo UH; Lee HJ; Kang J; Seo JH; Lee ES; Kim YH; Kim I; Phan-Lai V; Disis ML; Park KH
Breast Cancer Res Treat; 2014 Aug; 147(1):69-80. PubMed ID: 25104444
[TBL] [Abstract][Full Text] [Related]
15. Nanoliposomal vaccine containing long multi-epitope peptide E75-AE36 pulsed PADRE-induced effective immune response in mice TUBO model of breast cancer.
Zamani P; Teymouri M; Nikpoor AR; Navashenaq JG; Gholizadeh Z; Darban SA; Jaafari MR
Eur J Cancer; 2020 Apr; 129():80-96. PubMed ID: 32145473
[TBL] [Abstract][Full Text] [Related]
16. Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities.
Dakappagari NK; Lute KD; Rawale S; Steele JT; Allen SD; Phillips G; Reilly RT; Kaumaya PT
J Biol Chem; 2005 Jan; 280(1):54-63. PubMed ID: 15507452
[TBL] [Abstract][Full Text] [Related]
17. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.
Wang B; Zaidi N; He LZ; Zhang L; Kuroiwa JM; Keler T; Steinman RM
Breast Cancer Res; 2012 Mar; 14(2):R39. PubMed ID: 22397502
[TBL] [Abstract][Full Text] [Related]
18. HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells.
Miller MJ; Foy KC; Overholser JP; Nahta R; Kaumaya PT
Oncoimmunology; 2014 Nov; 3(11):e956012. PubMed ID: 25941588
[TBL] [Abstract][Full Text] [Related]
19. IGF-1R peptide vaccines/mimics inhibit the growth of BxPC3 and JIMT-1 cancer cells and exhibit synergistic antitumor effects with HER-1 and HER-2 peptides.
Foy KC; Miller MJ; Overholser J; Donnelly SM; Nahta R; Kaumaya PT
Oncoimmunology; 2014 Nov; 3(11):e956005. PubMed ID: 25941587
[TBL] [Abstract][Full Text] [Related]
20. Immunoprotective effect of an in silico designed multiepitope cancer vaccine with BORIS cancer-testis antigen target in a murine mammary carcinoma model.
Mahdevar E; Kefayat A; Safavi A; Behnia A; Hejazi SH; Javid A; Ghahremani F
Sci Rep; 2021 Nov; 11(1):23121. PubMed ID: 34848739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
